DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma (NCT04834674) | Clinical Trial Compass
CompletedPhase 2
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
China20 participantsStarted 2024-07-01
Plain-language summary
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above. Its incidence accounts for about 15%-20% of primary liver malignancies, showing a gradually increasing trend. Surgical resection is currently the main method for the treatment of ICC. However, most (60% -70%) patients are diagnosed at the advanced stage. Gemcitabine plus cisplatin is the standard first-line incurable resection recommended in international and domestic guidelines. There is not a standard second-line treatment that has progressed after standard first-line chemotherapy.
The clinical benefits of immune therapies for HCC are emerging. Early clinical data already show the safety of immune checkpoint inhibition. This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC that has progressed after standard first-line chemotherapy.
Patients who were aged 18 to 80 years with a histological or cytological diagnosis of ICC，locally advanced or multiple liver metastases, including progression after gemcitabine chemotherapy, will be enrolled in this trial.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. The diagnosis of ICC
✓. Patients must have at least one tumor lesion that can be accurately measured according to mRECIST criteria.
✓. Stand first-line chemotherapy resistance.
✓. Performance status (PS) ≤ 2 (ECOG scale).
✓. Child Pugh score ≤ 7.
✓. Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
✓. Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) \>1,500/mm3
✓. Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan
Exclusion criteria
✕. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
What they're measuring
1
objective response rate (ORR)
Timeframe: Change from baseline tumor volume at 6 months
2
progression free survival (PFS)
Timeframe: Up to 24 months, from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Trial details
NCT IDNCT04834674
SponsorSichuan Cancer Hospital and Research Institute